4.7 Article

Serum asymmetric dimethylarginine level correlates with the progression and prognosis of amyotrophic lateral sclerosis

Journal

EUROPEAN JOURNAL OF NEUROLOGY
Volume 29, Issue 5, Pages 1410-1416

Publisher

WILEY
DOI: 10.1111/ene.15254

Keywords

amyotrophic lateral sclerosis; biomarker; dimethylarginine

Funding

  1. Kanae Foundation for the Promotion of Medical Science and Japan Agency for Medical Research and Development [JP21wm0425013]

Ask authors/readers for more resources

This study found that serum ADMA level is associated with the progression and prognosis of amyotrophic lateral sclerosis (ALS) and is an independent biomarker for ALS disease progression and prognosis, reflecting the degree of motor neuron degeneration.
Background and purpose The aim was to investigate the association between serum asymmetric dimethylarginine (ADMA) levels and the progression and prognosis of amyotrophic lateral sclerosis (ALS), and to compare cerebrospinal fluid (CSF) and serum ADMA levels with other biomarkers of ALS. Methods Serum ADMA levels of sporadic ALS patients (n = 68), disease control patients (n = 54) and healthy controls (n = 20) were measured using liquid chromatography tandem mass spectrometry. Correlations of the ADMA level and other markers (nitric oxide and neurofilament light chain levels) were analyzed. Changes in the ALS Functional Rating Scale Revised (ALSFRS-R) score from the onset of disease (ALSFRS-R pre-slope) was used to assess disease progression. Survival was evaluated using the Cox proportional hazards model and Kaplan-Meier analysis. Results The serum ADMA level was substantially higher in patients with ALS than in healthy controls and disease controls. Serum ADMA level correlated with CSF ADMA level (r = 0.591, p < 0.0001) and was independently associated with the ALSFRS-R pre-slope (r = 0.505, p < 0.0001). Patients with higher serum ADMA levels had less favorable prognoses. CSF ADMA level significantly correlated with CSF neurofilament light chain level (r = 0.456, p = 0.0002) but not with nitric oxide level (r = 0.194, p = 0.219). Conclusion Serum ADMA level is an independent biomarker of ALS disease progression and prognosis and reflects the degree of motor neuron degeneration.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available